Little more than six months after opening at $20 after pricing its initial public offering, Zafgen Inc. impressed investors by reporting that beloranib, its methionine aminopeptidase 2a (MetAP2) inhibitor, met the primary efficacy endpoint of weight reduction in a small phase II trial in patients with hypothalamic injury associated obesity, or HIAO.